PRA Expands Trial Capabilities in Asia

PRA Taiwan, a subsidiary of PRA International, has entered a strategic partnership with LSK Global Pharma Services and Mediscience Planning for the joint management of multinational clinical trials in Asia as well as related services, such as study monitoring and data management.

The partnership adds to PRA’s capabilities in Asia with regulatory intelligence and investigator sites in Japan through Mediscience, and in South Korea through LSK.

“We are very pleased to broaden our Asian capabilities through this partnership,” said Susan Stansfield, executive vice president of product registration for Europe, Africa and Asia-Pacific. “Through this collaboration, we are strongly positioned to meet the growing demand for pan-Asian clinical trials.”

“Formalizing our relationships with Mediscience and LSK is an important step for our company,” added Edward Ian, senior director of Clinical Operations, PRA – Asia Pacific. “This partnership will further improve our ability to promote and execute regional clinical trials in Japan, Taiwan, and Korea.”